Inclusion Criteria:

- Non-Small-Cell Lung cancer cytologically or histologically proved

- Stage III AN2 inoperable or non resectable

- presence of at least one one dimension measurable target (at least 10 mm with spiral
tomodensitometry)

- Possibility to include all targets in one irradiation field

- Age of 18 to 70

- Patients non previously treated

- Performance Status 0 or 1

- Loss of weight ≤10% in the 3 last months

- Neutrophil ≥ 1500/mm3 and platelets ≥ 100000/mm3

- Creatinine clearance ≥ 60 ml/min

- total bilirubin ≤ 1,5N and ASAT ALAT ≤ 2,5N

- Respiratory function normal: VEMS ≥ 40% theorical, DLCO/VA ≥ 50% theorical and PaO2 ≥
60 mmHg

- Signed inform consent form

- Compliance to radiotherapy 66 Gy with dosimetry V20 ≤ 35% and pulmonary mean dose≤20
Gy

Exclusion Criteria:

- Pretreated bronchial carcinoma, excepted endoscopic deobstruction

- operable bronchial carcinoma

- small cell lung cancer, composite cancer, neuroendocrine cancer, broncho alveolar
cancer

- superior vena cava syndroms

- puncturable pleural effusion

- metastatic lung cancer

- Stage IIIb cancer with neoplastic pericarditis

- Previous thoracic irradiation

- severe cardiac disease in the 12 months before inclusion

- interstitial lung disease

- anti-EGFR and anti-VEGF treatments

- hypersensitivity to murine proteins and allergies to protocol drugs

- uncontrolled infectious state

- HIV patient

- corticoid definitive contraindication

- péripheric neuropathy grade≥2

- neurologic, psychiatric and organic disorder

- past or concomitant cancer excepted treated skin baso-cellular cancer or in situ
cervical cancer, or any cancer only surgically treated for 5 years

- breastfeeding woman